India eyes Russia, Brazil, Netherlands for pharma export growth as US tariffs concerns linger

India plans to diversify its pharmaceutical export markets, targeting Russia, Brazil, and the Netherlands, to mitigate risks from potential U.S. tariffs and reduce reliance on its largest market. While the U.S. accounts for over a third of India's pharma exports, this strategy aims to leverage existing manufacturing capacity to potentially increase exports to new markets by 20%, complementing rather than substituting crucial U.S. revenue. The move seeks to broaden India's global market share, with regulatory discussions planned to facilitate expansion, and an expected boost in UK exports following a free trade agreement.

Analysis

India's pharmaceutical sector is initiating a strategic diversification of its export markets to mitigate geopolitical risk, specifically the uncertainty surrounding potential U.S. tariffs. While the U.S. remains the primary market, accounting for over a third of exports and growing 20% to $10.5 billion in fiscal 2025, the industry is targeting Russia, Brazil, and the Netherlands for expansion. This move is positioned as supplementary, not a substitute for U.S. revenue, with an aim to leverage existing manufacturing capacity for a potential 20% increase in exports to these new regions. The strategy is reinforced by a separate focus on the UK, where a new free trade agreement is expected to significantly boost procurement of Indian generics and APIs. However, this expansion is a long-term play contingent on overcoming regulatory hurdles in the target countries, a key topic for upcoming industry discussions, reflecting a cautious but strategically sound approach to de-risking the supply chain and broadening the sector's global footprint.

Key Decisions for Investors

• Investors should view this diversification as a long-term positive for the Indian pharmaceutical sector, but monitor for tangible progress on regulatory approvals in Russia, Brazil, and the Netherlands, as these are cited as key near-term obstacles.
• While diversification is the theme, the U.S. market's performance remains the most critical short-to-medium term value driver, so any developments on U.S. generic pricing or tariff policies will continue to have an outsized impact on sector earnings.
• Consider evaluating pharmaceutical companies based on their existing non-U.S. export exposure and their stated strategies for capitalizing on new growth from the UK free trade agreement and emerging markets.